Form 4: BioMarin Executive Charles Guyer Acquires Shares Through RSU Vesting

Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., acquired shares of common stock through the vesting of Restricted Stock Units (RSUs) based on performance metrics.

Summary

• Charles Greg Guyer, an executive at BioMarin Pharmaceutical Inc., acquired shares of the company's common stock on February 25, 2025.
• The acquisition was through the vesting of Restricted Stock Units (RSUs).
• These RSUs were earned based on performance metrics related to total shareholder return, development goals, and core operating margin over the periods 2022-2024.
• A total of 11,040 RSUs were earned based on relative total shareholder return.
• 9,660 RSUs were earned based on the number and nature of development goals achieved.
• 9,367 RSUs were earned based on core operating margin.
• The RSUs vest on March 15, 2025, subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it indicates that performance goals were met, leading to the vesting of RSUs for a key executive. This suggests that the company is performing well and that management is incentivized to continue driving growth.

Positives

• The vesting of RSUs indicates that performance goals related to shareholder return, development goals, and operating margin were met during the 2022-2024 period.
• The executive's increased stake in the company aligns his interests with those of shareholders.

Future Outlook

The RSUs vest on March 15, 2025, subject to the reporting person's continued service through that date.

Industry Context

Executive compensation through equity grants is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize performance.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded biotechnology companies such as Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX).
• The specific metrics used to determine RSU vesting (shareholder return, development goals, and operating margin) are common performance indicators in the industry.
• The vesting schedule of the RSUs is typical, with vesting contingent on continued employment.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign, indicating that the company is achieving its performance goals.
• Employees may be motivated by the fact that executives are being rewarded for their performance.

Next Steps

• The RSUs will vest on March 15, 2025, assuming continued service of the reporting person.

Key Dates